PixarBio Corp. To Establish Medical Research Center-Corporate Headquarters In Medford, Massachusetts
12/13/2013
Located in close proximity to its innovation roots at Harvard and MIT, PixarBio Corp. said it will have capacity to quickly expand beyond biomaterials needed for Parkinson’s disease to include biomaterials for Epilepsy.
“We are building a home for our world renowned and award winning team of researchers to drive innovation and accelerate the development of new treatment options for Parkinson’s disease. We’re confident that our optimized R&D model will generate key intellectual property permitting PixarBio to lead the development of next generation biomaterials for the treatment of Parkinson’s disease as well as a range of chronic neurological conditions,” says CTO Randy Holmes-Farley, PhD.
Frank Reynolds, PixarBio’s CEO adds, “We’ll move to Medford, MA in early 2014 and get to work on achieving our objective of rapidly bringing a new Parkinson’s treatment to market. Along the way we’ll explore M&A in the biomaterials space while focusing on expanding our platform.”
Project Announcements
Alnylam Pharmaceuticals Expands Norton, Massachusetts, Research Operations
12/29/2025
Salvagnini America Expands Hamilton, Ohio, Operations
12/28/2025
Hims & Hers Health Expands New Albany, Ohio, Operations
12/28/2025
Poly6 Technologies Expands Eastlake, Ohio, Operations
12/26/2025
Ohio Lumex Expands Solon, Ohio, Operations
12/26/2025
Calgon Carbon Corporation Expands Pittsburgh, Pennsylvania, Operations
12/25/2025
Most Read
-
The Workforce Bottleneck in America’s Manufacturing Revival
Q4 2025
-
Rethinking Local Governments Through Consolidation and Choice
Q3 2025
-
Lead with Facts, Land the Deal
Q3 2025
-
Tariff Shockwaves Hit the Industrial Sector
Q4 2025
-
Investors Seek Shelter in Food-Focused Real Estate
Q3 2025
-
America’s Aerospace Reboot
Q3 2025
-
The Permit Puzzle and the Path to Groundbreaking
Q3 2025